Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
75.60
+0.47 (0.63%)
Apr 25, 2025, 12:00 PM EDT - Market open
Edwards Lifesciences Revenue
Edwards Lifesciences had revenue of $1.41B in the quarter ending March 31, 2025, with 4.89% growth. This brings the company's revenue in the last twelve months to $5.52B, down -9.68% year-over-year. In the year 2024, Edwards Lifesciences had annual revenue of $5.44B with 8.57% growth.
Revenue (ttm)
$5.52B
Revenue Growth
-9.68%
P/S Ratio
8.08
Revenue / Employee
$349,513
Employees
15,800
Market Cap
44.28B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.44B | 429.50M | 8.57% |
Dec 31, 2023 | 5.01B | 546.00M | 12.23% |
Dec 31, 2022 | 4.46B | -768.50M | -14.69% |
Dec 31, 2021 | 5.23B | 846.20M | 19.29% |
Dec 31, 2020 | 4.39B | 38.30M | 0.88% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
EW News
- 21 hours ago - Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens - Benzinga
- 1 day ago - Edwards Lifesciences Corporation (EW) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Edwards Lifesciences raises 2025 sales forecast after robust quarter - Reuters
- 1 day ago - Edwards Lifesciences Reports First Quarter Results - Business Wire
- 7 days ago - Eight-Year Data Confirm Long-Term Durability of Edwards' RESILIA Tissue - Business Wire
- 9 days ago - Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - Business Wire
- 11 days ago - Edwards SAPIEN M3 Receives CE Mark, Becoming World's First Transfemoral Transcatheter Mitral Valve Replacement System - Business Wire
- 24 days ago - New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients - Business Wire